Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled pilot study of KB001 in mechanically-ventilated patients colonized with Pseudomonas aeruginosa
2007-006764-29Phase 2Active
- Sponsor
- KaloBios Pharmaceuticals
- Start
- Jan 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KB-001 in ventilator-associated pneumonia (VAP), Ventilator-associated pneumonia due to Pseudomonas aeruginosa infection and Pseudomonas aeruginosa pulmonary infection (3 arms), sponsored by KaloBios Pharmaceuticals. Primary endpoint: Safety and tolerability of a single dose of KB001. Started Jan 2008; status: active.
02
Drugs
KB-001
03
Conditions
ventilator-associated pneumonia (VAP)Ventilator-associated pneumonia due to Pseudomonas aeruginosa infectionPseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on 2007-006764-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006764-29.